Table 4 Clinicopathological features of PTMC-FV cases with respect to BRAF and NRAS mutations.
Variables | BRAF mutation n (%) n = 4 | No BRAF mutation n (%) n = 11 | P-value | NRAS mutation n (%) n = 5 | No NRAS mutation n (%) n = 8 | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | 1.000 | 0.724 | ||||||||
Mean ± SD | 46.7 ± 14.7 | 47.3 ± 13.2 | 46.0 ± 14.2 | 44.4 ± 12.4 | ||||||
Gender | 1.000 | 0.385 | ||||||||
Female | 4 | (100.0) | 9 | (81.8) | 4 | (80.0) | 8 | (100.0) | ||
Male | 0 | (0.0) | 2 | (18.2) | 1 | (20.0) | 0 | (0.0) | ||
Stage | 0.476 | 1.000 | ||||||||
I | 3 | (75.0) | 10 | (90.9) | 4 | (80.0) | 7 | (87.5) | ||
II | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
III | 1 | (25.0) | 1 | (9.1) | 1 | (20.0) | 1 | (12.5) | ||
IV | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
Not available | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
Focality | 0.604 | 0.565 | ||||||||
Unifocal | 3 | (75.0) | 6 | (54.5) | 4 | (80.0) | 4 | (50.0) | ||
Multifocal | 1 | (25.0) | 5 | (45.5) | 1 | (20.0) | 4 | (50.0) | ||
Not available | 0 | (0.0) | 0 | (0.0) | ||||||
Extrathyroidal extension | 0.476 | 1.000 | ||||||||
Present | 1 | (25.0) | 1 | (9.1) | 1 | (20.0) | 1 | (12.5) | ||
Absent | 3 | (75.0) | 10 | (90.9) | 4 | (80.0) | 7 | (87.5) | ||
Not available | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
Lymphovascular invasion | 0.267 | NA | ||||||||
Present | 1 | (25.0) | 0 | (0.0) | (0.0) | (0.0) | ||||
Absent | 3 | (75.0) | 11 | (100.0) | 5 | (100.0) | 8 | (100.0) | ||
Not available | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
Lymphnodes status | 1.000 | 1.000 | ||||||||
Positive | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | ||
Negative | 1 | (25.0) | 2 | (18.2) | 1 | (20.0) | 2 | (25.0) | ||
Not available | 3 | (75.0) | 9 | (81.8) | 4 | (80.0) | 6 | (75.0) | ||
